N-乙酰半胱氨酸在慢性阻塞性肺疾病急性加重患者的疗效观察  

Effects of N-Acetylcysteine in COPD Exacerbations

作　　者：王晓霞[1] 殷俊[1] 练详忠[1] 高蜀生[1] 

机构地区：[1]成都市第三人民医院呼吸科,四川成都610031

出　　处：《华西医学》2008年第3期517-518,共2页West China Medical Journal

摘　　要：目的:观察N-乙酰半胱氨酸(NAC)在治疗急性加重期慢性阻塞性肺疾病患者(AECOPD)的疗效及耐受性。方法:122例AECOPD患者随机分成二组,除常规治疗外,治疗组加用NAC600μg/天,对照组不用NAC,治疗15天后观察C反应蛋白(CRP)正常率、血气分析、症状改善、肺功能及耐受性。结果:CRP正常率两组均比治疗前明显升高,治疗后治疗组比对照组CRP正常率也明显增高(86·7%vs65·5%,P<0·05);PaO2及PaCO2变化:组内比较:治疗组及对照组均比治疗前PaO2明显升高(P<0·05),PaCO2明显下降(P<0·05)。组间比较:治疗后PaO2治疗组比对照组明显升高(P<0·05),PaCO2未见显著差异(P>0·05);临床症状改善:治疗组比对照组总有效率明显升高(90%vs74·1%P<0·05),临床症状改善明显;肺功能:治疗组FEV1及FVC均比治疗前明显改善(P<0·05),而对照组治疗前后无显著差异(P>0·05);治疗过程中二组耐受性均良好,未见较为严重的不良反应。结论:口服NAC600μg/天治疗可以明显改善AECOPD的CRP水平和临床症状,改善氧饱和度及肺功能,耐受性好。Objective：To evaluate the clinical efficacy and safety of N-Acetylcysteine（NAC）in treatment of COPD exacerbations.Methods：One hundred and twenty-two COPD exacerbations entered the parallel.randomized clinical trail,62 in study group were received NAC,600mg/day based on routine therapy,60 in control group were received the routine therapy only. Results：The normal rate of CRP in NAC group is higher than the control group （86.7% Vs 65.5%,P〈0.05） after treatment.PaO2 was increased obviously in the NAC group than the control （P〈0.05）,PCO2 was found no significant difference （P〈0.05）.The effective rate of NAC was 90% and that control was 74.1%（P〈0.05）, FEV1 and FVC were improved after treatment in NAC group and the control had no significant change in FEV1 and FVC.There was no significant adverse effect in both group. Conclusion：NAC is an effective and well tolerated oral agent in treatment COPD exacerbations

关 键 词：N-乙酰半胱氨酸 AECOPD 疗效 

分 类 号：R563.9[医药卫生—呼吸系统]